HOME >> MEDICINE >> NEWS
Incubation period for human BSE infection could exceed 50 years

A person could possibly be infected with bovine spongiform encephalopathy (BSE) prions for over 50 years before developing variant Creutzfeldt-Jakob disease (vCJD), according to a study on another human prion disease called kuru in this week's issue of The Lancet. The findings suggest that the eventual size of a vCJD epidemic could be much bigger than previously thought, state the authors.

Dietary exposure of the UK population to BSE prions has been widespread. So far, around 160 vCJD patients have been identified in the UK, with cases also reported in France, Italy, Ireland, the Netherlands, Canada, Japan, and the USA. Predictions of the eventual size of a vCJD epidemic have varied widely; recent estimates, based on the current numbers of VCJD patients, have suggested that the total epidemic may be relatively small. However, the incubation period for BSE in people is key in predicting the true extent of an epidemic, and this has been unknown until now.

John Collinge (University College London, UK) and colleagues studied the only example of a major human prion disease epidemic available - a disease called kuru. Kuru is caused by cannibalism and reached epidemic proportions in certain communities in Papa New Guinea, where the consumption of dead relatives, as a mark of respect and mourning, was ritual practise. Its incidence fell steadily after Australian authorities stopped the practise in the 1950s.

In the study the investigators identified 11 patients with kuru from July 1996 to June 2004. As the latest year of birth recorded for a patient with kuru is 1959, the authors assumed that transmission by cannabilism ceased by 1960. They worked out the minimum incubation period for the disease as the time between 1960 and the date of onset of kuru in the patients. They found that the minimum incubation periods ranged from 34 to 41 years. However, in men more accurate assessment was possible and estimated incubation periods ranged from 39 to 56 ye
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
22-Jun-2006


Page: 1 2

Related medicine news :

1. New evidence finds an association between periodontal disease and stroke
2. New study finds a positive association between periodontal disease and coronary heart disease
3. The effect of periodontal disease on health care costs
4. Progulske-Fox receives periodontal disease research award
5. Chronic stress, depression and cortisol levels are potential risk indicators for periodontal disease
6. Earlier periodontal treatment leads to lower medical costs
7. Obesity is a significant predictor of periodontal disease
8. Severe periodontal disease is more frequent among socioeconomically disadvantaged individuals
9. Antibiotics do not prevent recurrent myocardial infarcts in subjects with periodontitis
10. Psychotropic drug prescriptions for teens surge 250 percent over 7 year period
11. HIV-positive patients have shorter survival periods while awaiting liver transplants

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Incubation period for human BSE infection could exceed years

(Date:5/21/2013)... An attack on glioblastoma brain tumor cells that ... an early study to establish the proper dose level, ... developed at Duke and tested in an ongoing phase ... have an abundance of receptors that work like magnets ... cells. , The investigational therapy, known as PVSRIPO, ...
(Date:5/21/2013)... Adeptia, a leading provider of innovative cloud ... is the featured company in an impact report written ... “Adeptia Bets on Converged Cloud Integration and Process-Orchestration Suites,” ... products, pricing, customers and competition. , “For ... integration and process orchestration, especially when price, ease of ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... Grapefruits have long been known for their ... how medical therapies like anti-cancer drugs are delivered ... researchers have uncovered how to create nanoparticles using ... how to use them as drug delivery vehicles. ... Ph.D., and their team today (May 21, 2013), ...
(Date:5/21/2013)... May 21, 2013 Benefit Express Services, ... medium, and small organizations, will be hosting a free ... team from Findley Davies. The presentation will focus on ... in compliance with new Health Care Reform Requirements. The ... employees. , “Benefit Express regularly hosts free educational ...
Breaking Medicine News(10 mins):Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:Adeptia Featured in Recent 451 Research Impact Report 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)... 2013  BioRestorative Therapies, Inc. ("BRT" or the "Company") ... developing stem cell based therapies for various personal applications, ... President and CEO, will be presenting at the Marcum ... held on Thursday, May 30, 2013 at the Grand ... New York City.  Mr. Weinreb,s presentation will take place ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
Cached News: